{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=latanoprost+ophthalmic+solution&page=4", "query": { "intervention": "latanoprost ophthalmic solution", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 73, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=latanoprost+ophthalmic+solution&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=latanoprost+ophthalmic+solution&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T04:34:32.038Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00287521", "title": "A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Open-angle Glaucoma", "Ocular Hypertension" ], "interventions": [ { "name": "AL-37807 Ophthalmic Suspension, 1.0%", "type": "DRUG" }, { "name": "Latanoprost, 0.005% (Xalatan)", "type": "DRUG" }, { "name": "AL-37807 Vehicle", "type": "OTHER" }, { "name": "Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alcon Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2005-11", "completion_date": "2006-02", "has_results": false, "last_update_posted_date": "2012-03-05", "last_synced_at": "2026-10-04T04:34:32.038Z", "location_count": 1, "location_summary": "Fort Worth, Texas", "locations": [ { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00287521" }, { "nct_id": "NCT03293992", "title": "A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glaucoma, Open-angle", "Ocular Hypertension" ], "interventions": [ { "name": "0.01% RO7058584", "type": "DRUG" }, { "name": "0.1% RO7058584", "type": "DRUG" }, { "name": "1% RO7058584", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" }, { "name": "Latanoprost 0.005%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 27, "start_date": "2017-10-10", "completion_date": "2017-12-21", "has_results": false, "last_update_posted_date": "2020-03-31", "last_synced_at": "2026-10-04T04:34:32.038Z", "location_count": 8, "location_summary": "Chandler, Arizona • Artesia, California • Inglewood, California + 5 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Artesia", "state": "California" }, { "city": "Inglewood", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03293992" }, { "nct_id": "NCT06964191", "title": "Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glaucoma, Open-Angle", "Ocular Hypertension" ], "interventions": [ { "name": "PA5108 Ocular Implant low dose", "type": "COMBINATION_PRODUCT" }, { "name": "PA5108 Ocular Implant, high dose", "type": "COMBINATION_PRODUCT" }, { "name": "Latanoprost 0.005% Ophthalmic Solution", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "PolyActiva Pty Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2025-05-31", "completion_date": "2026-11-15", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-10-04T04:34:32.038Z", "location_count": 1, "location_summary": "Newport Beach, California", "locations": [ { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06964191" }, { "nct_id": "NCT02059278", "title": "Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Open Angle Glaucoma", "Ocular Hypertension" ], "interventions": [ { "name": "T-2345", "type": "DRUG" }, { "name": "Xalatan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nephron Pharmaceuticals Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 335, "start_date": "2014-01", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2018-08-22", "last_synced_at": "2026-10-04T04:34:32.038Z", "location_count": 1, "location_summary": "El Paso, Texas", "locations": [ { "city": "El Paso", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02059278" }, { "nct_id": "NCT01917383", "title": "A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Open-Angle Glaucoma (POAG)", "Ocular Hypertension (OHT)" ], "interventions": [ { "name": "Trabodenoson", "type": "DRUG" }, { "name": "Latanoprost", "type": "DRUG" }, { "name": "Timolol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inotek Pharmaceuticals Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2013-08", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2017-12-02", "last_synced_at": "2026-10-04T04:34:32.038Z", "location_count": 1, "location_summary": "Bristol, Tennessee", "locations": [ { "city": "Bristol", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01917383" }, { "nct_id": "NCT00650338", "title": "Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Open-Angle Glaucoma", "Ocular Hypertension" ], "interventions": [ { "name": "DE-104 ophthalmic solution, low concentration", "type": "DRUG" }, { "name": "DE-104 ophthalmic solution, medium concentration", "type": "DRUG" }, { "name": "DE-104 ophthalmic solution, high concentration", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "0.005% latanoprost", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Santen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2008-03", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2011-11-03", "last_synced_at": "2026-10-04T04:34:32.038Z", "location_count": 14, "location_summary": "Artesia, California • Los Angeles, California • Torrance, California + 9 more", "locations": [ { "city": "Artesia", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Stuart", "state": "Florida" }, { "city": "Bel Air", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00650338" }, { "nct_id": "NCT01731002", "title": "Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ocular Hypertension", "Open Angle Glaucoma" ], "interventions": [ { "name": "AR-13324 Ophthalmic Solution 0.01%", "type": "DRUG" }, { "name": "AR-13324 Ophthalmic Solution 0.02%", "type": "DRUG" }, { "name": "Latanoprost ophthalmic solution 0.005%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aerie Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 224, "start_date": "2012-11", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2018-04-17", "last_synced_at": "2026-10-04T04:34:32.038Z", "location_count": 22, "location_summary": "Artesia, California • Inglewood, California • Newport Beach, California + 19 more", "locations": [ { "city": "Artesia", "state": "California" }, { "city": "Inglewood", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Petaluma", "state": "California" }, { "city": "Poway", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01731002" }, { "nct_id": "NCT06407973", "title": "A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Primary Open Angle Glaucoma" ], "interventions": [ { "name": "OMNI Surgical System", "type": "DEVICE" }, { "name": "Latanoprost plus adjunctive glaucoma medication", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Sight Sciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": null, "sex": "ALL", "summary": "45 Years and older" }, "enrollment_count": 2, "start_date": "2024-08-21", "completion_date": "2025-01-20", "has_results": false, "last_update_posted_date": "2025-01-29", "last_synced_at": "2026-10-04T04:34:32.038Z", "location_count": 2, "location_summary": "Petaluma, California • Maryville, Tennessee", "locations": [ { "city": "Petaluma", "state": "California" }, { "city": "Maryville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06407973" }, { "nct_id": "NCT00847483", "title": "Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Glaucoma", "Ocular Hypertension" ], "interventions": [ { "name": "latanoprost 0.005% ophthalmic solution", "type": "DRUG" }, { "name": "Travoprost 004% sterile ophthalmic solution", "type": "DRUG" }, { "name": "Bimatoprost .03% sterile ophthalmic solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 375, "start_date": "2002-01", "completion_date": "2002-08", "has_results": false, "last_update_posted_date": "2021-02-02", "last_synced_at": "2026-10-04T04:34:32.038Z", "location_count": 40, "location_summary": "Bellflower, California • Inglewood, California • San Diego, California + 31 more", "locations": [ { "city": "Bellflower", "state": "California" }, { "city": "Inglewood", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00847483" }, { "nct_id": "NCT00705757", "title": "The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Glaucoma", "Application Site Pigmentation Changes" ], "interventions": [ { "name": "latanoprost", "type": "DRUG" }, { "name": "bimatoprost", "type": "DRUG" }, { "name": "travoprost", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Summa Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 89, "start_date": "2008-03", "completion_date": "2011-04", "has_results": true, "last_update_posted_date": "2016-01-18", "last_synced_at": "2026-10-04T04:34:32.038Z", "location_count": 2, "location_summary": "Arlington Heights, Illinois • Akron, Ohio", "locations": [ { "city": "Arlington Heights", "state": "Illinois" }, { "city": "Akron", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00705757" } ] }